The startup develops implantable biomaterials that enhance stem cell therapy for the human brain, specifically targeting the survival and differentiation of stem cells into neurons after implantation. Their technology provides cell therapies for neurodegenerative diseases, enabling the regeneration of neuronal networks in conditions like Parkinson's Disease.
Funding
$250K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current stem cell therapies for neurodegenerative diseases face challenges in ensuring the survival and differentiation of implanted stem cells into functional neurons within the brain. The harsh environment of the brain, coupled with limited control over stem cell fate, hinders effective regeneration of neuronal networks.
Solution
Convalesce develops implantable biomaterials designed to enhance stem cell therapy outcomes for neurodegenerative diseases. These biomaterials create a supportive microenvironment that promotes the survival and differentiation of stem cells into neurons after implantation in the brain. By improving cell engraftment and neuronal network regeneration, Convalesce aims to provide more effective cell therapies for conditions like Parkinson's Disease and other neurological disorders. The technology focuses on optimizing the interaction between stem cells and the host tissue to facilitate functional recovery.
Target Audience
The primary target audience includes researchers and clinicians focused on developing and implementing stem cell therapies for neurodegenerative diseases, as well as pharmaceutical companies specializing in neurological treatments.
Features
- Biomaterial scaffolds designed for implantation in the brain.
- Enhanced stem cell survival and differentiation into neurons.
- Promotion of neuronal network regeneration.
- Optimized microenvironment for cell engraftment.